Shares of OncoCyte Corp (NYSEAMERICAN:OCX) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $6.67.
Several research firms have commented on OCX. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a report on Tuesday, January 29th. Lake Street Capital restated a “buy” rating on shares of OncoCyte in a report on Wednesday, December 19th. Zacks Investment Research upgraded OncoCyte from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a report on Thursday, January 17th. Piper Jaffray Companies began coverage on OncoCyte in a report on Wednesday, February 13th. They issued an “overweight” rating and a $6.00 price target for the company. Finally, began coverage on OncoCyte in a report on Monday, October 29th. They issued a “positive” rating for the company.
In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 533,333 shares of the business’s stock in a transaction on Friday, February 8th. The shares were bought at an average cost of $3.75 per share, with a total value of $1,999,998.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
A hedge fund recently raised its stake in OncoCyte stock. Vanguard Group Inc grew its position in OncoCyte Corp (NYSEAMERICAN:OCX) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 410,275 shares of the biotechnology company’s stock after purchasing an additional 15,115 shares during the period. Vanguard Group Inc owned about 1.01% of OncoCyte worth $1,026,000 at the end of the most recent quarter.
OncoCyte stock traded up $0.01 during midday trading on Wednesday, reaching $3.82. 478,796 shares of the company were exchanged, compared to its average volume of 2,058,518. OncoCyte has a 1 year low of $1.10 and a 1 year high of $6.92.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Recommended Story: QQQ ETF
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.